The impact of peripheral blood stem cell transplantation (PBSCT) on survival relative to bone marrow transplantation (BMT) remains poorly defined. Several randomized controlled trials (RCTs) comparing HLA-matched related PBSC-and BMT for patients with hematologic malignancies have been published, yielding differing results. We conducted a meta-analysis of published RCTs to more precisely estimate the effect of PBSCT on survival. Seven trials that assessed survival were identified and included in our analysis. Using a fixed effects model, and combining the results of all seven trials, the summary odds ratio for mortality after PBSCT was 0.81 (95% CI, 0.62-1.05) when compared to BMT. Subgroup analysis revealed no association between the median PBSCT 34+ cell dose and relative risk for morality after PBSCT. However, there was an association between the proportion of patients enrolled with advanced-stage disease and the summary odds ratio for mortality. The pooled estimate was 0.64 for studies where patients with intermediate/ advanced disease comprised at least 25% of enrollment, and was 1.07 for the studies enrolling a smaller proportion. This finding substantiates results from previously published studies that have demonstrated a survival advantage with PBSCT limited to patients with advanced disease.
The use of allogeneic cytokine mobilized peripheral blood stem cell transplantation (PBSCT) has increased considerably as a treatment for hematologic malignancies. 1 This increase has been stimulated by the recognition that PBSCT has certain advantages relative to bone marrow transplantation (BMT), including more rapid granulocyte and platelet engraftment, shorter hospitalization time and quicker immune reconstitution. [2] [3] [4] [5] [6] [7] There also appear, however, to be certain disadvantages to PBSCT, such as a higher incidence of chronic graft-versus-host disease (GVHD). 2, 8 There is less certainty regarding the relative impact of PBSCT on survival. Data from four multicenter randomized controlled trials (RCTs) are conflicting. Significantly improved overall survival was reported with PBSCT in one study, and a strong trend in the same direction was noted in another study. 3, 6 The other two studies demonstrated no difference. 5, 7 The results of smaller single center trials have also been inconsistent. [9] [10] [11] It is likely, particularly because of the relatively small size of several of these studies, that the discrepant results are partly attributable to random variation; however, differences in the patient populations and transplant protocols may have also contributed. Most notably, there has been considerable between-study variation in the proportion of patients enrolled with advancedstage disease and in the targeted and median transplanted PBSCT cell doses. Importantly, retrospective studies by the European Blood and Marrow Transplant Group and the International Bone Marrow Transplant Registry suggest that any survival advantage associated with PBSCT may be restricted to patients with more advanced disease. 2, 12 Higher cell dose has been shown to improve survival after allogeneic BMT and cord blood transplantation, and a similar relation may exist between cell dose and PBSCT. [13] [14] [15] [16] [17] [18] Meta-analysis is a statistical method, which is often employed to summarize the results of several studies of a treatment or other intervention. There are two general components of this methodology. First, it is used to combine studies to summarize the effect of a treatment on a specified outcome. Since combining the relevant studies increases statistical power, it is particularly useful in settings such as the present one, where many of the trials have been insufficiently powered to reach statistical significance for the outcome of interest, in this case survival. 19 The second and less well-known component is referred to as the 'exploration of heterogeneity.' This represents an attempt to explain the variability in outcomes across studies by identifying differences in patient populations and study methodology that underlie this variability. 19 We performed a meta-analysis of published RCTs comparing HLA-matched sibling PBSCT and BMT to calculate a summary estimate of the treatment effect on mortality. We also conducted an exploration of heterogeneity, addressing the relation between differences in survival and differences in the proportion of patients with advanced disease and median PBSCT CD34+ cell dose.
Methods

Information retrieval
Only studies published as an abstract or journal article were eligible for this analysis. Relevant studies were identified through a computerized literature search of the Medline, Cancerlit and Cochrane databases. Two subject headings were employed: Bone Marrow Transplantation and Hematopoietic Stem Cell Transplantation. The search was then narrowed by using a boolean combination with the keyword allogeneic and then by limiting the publication type to randomized clinical trials. Studies published by 1 September 2002 were eligible. The abstracts of the retrieved publications were reviewed, and those studies meeting the prespecified criteria were selected for the analysis.
Only randomized controlled studies that assessed survival as an outcome, and were designed to compare the efficacy of HLA-matched related PBSCT and BMT, were eligible. Studies where survival was not assessed and studies employing observational designs, such as case series or case-control studies, were not eligible. The reference lists of review articles, meta-analyses, and of all the selected publications were used to identify other potential studies.
Data extraction
The principal investigator extracted the data from the articles or abstracts, using preprinted extraction forms. Data were collected regarding patient characteristics (eg age, sex, disease, disease stage), trial design and treatment protocol (eg G-CSF dosing, preparative regimen, GVHD prophylaxis), graft characteristics (CD34+ cell dose), and overall mortality. Primary authors were contacted as needed to clarify data.
Statistical analysis
The relative risk of mortality or hazard ratio following PBSCT (compared to bone marrow) was estimated for each study based on the odds ratio of mortality. An overall summary estimate was estimated utilizing the Peto modification of the Mantel-Haenzel method, combining the rates from the individual randomized controlled trials, each weighted in inverse proportion to the variance of the estimate. 20 In meta-analysis there are two general statistical models for calculating summary estimates: the fixed effects and random effects models. In the fixed effects model, inference is conditional on the studies actually done, which assumes that the true effect of treatment is the same for all studies. The random effects model, on the other hand, assumes that the studies are a random sample of some hypothetical population of studies. 19 The Mantel-Haenszel method is a fixed effects method and assumes that all studies are estimating the same true treatment effect. 21 These two approaches generally differ in practice only when there is substantial between-study variation or heterogeneity. To assess heterogeneity and to be certain that it was appropriate to combine the individual study risk estimates, we conducted a w 2 test for heterogeneity which takes into account the degree that individual study estimates deviate from the summary risk estimate. If the corresponding P-value is less than 0.05, excessive betweenstudy differences or heterogeneity are deemed to be present. This is typically considered to be a contraindication to pooling data for a summary estimate. 22 We also performed an exploration of heterogeneity using subgroup analyses. With meta-analyses that include a large number of studies, multivariate regression analysis is sometimes feasible, but the small number of trials included in our study precluded such an analysis. 19 Two subgroup analyses were performed. For the first, the studies were stratified into two groups according to the median CD34+ cell/kg dose for PBSC transplants, using 4 Â 106 CD34+ cells/kg as a cutoff. For the second, the studies were stratified into two groups according to the proportion of patients enrolled with intermediate or advanced disease, using 25% as a cutoff. In each instance, we chose cutoffs that we thought were clinically meaningful and that subdivided the studies into reasonably sized subgroups. For the second analysis, the International Bone Marrow Transplant Registry definitions of early, intermediate, and advanced leukemia were employed (early ¼ acute leukemia in 1st CR or CML in 1st CP, intermediate ¼ acute leukemia in X2nd CR or CML in accelerated phase, advanced ¼ acute leukemia in relapse or CML in blast crisis). 23 For myelodysplasia, refractory anemia without excess blasts was considered early-stage disease, and other forms were considered as intermediate/advanced. All other hematologic malignancies were assumed to be intermediate/advanced. The 95% confidence intervals were calculated for both the study-specific relative risks and the summary estimates.
The accuracy of a meta-analysis, which, like ours, relies solely on published studies, is potentially diminished by publication bias. This bias, which is a result of the tendency against the publication of small negative studies, may result in the overestimation of the potential benefit of a treatment. Although other approaches have been developed to detect publication bias in meta-analysis, we employed the most widely accepted approach, a funnel plot. 19, 24 Data were analyzed using SAS for Windows v8.1 (SAS Institute, Inc. Cary, NC, USA) and Review Manager 4.1.1 (Cochrane Collaboration).
Results
Literature review
In all, 281 abstracts were identified through the computerized literature search. Nine articles regarding seven randomized controlled trials comparing the efficacy of allogeneic PBSCT and BMT were identified. 25, 26 Two articles were published on a European Group for Blood and Marrow Transplantation Trial, the first being an interim analysis. Only the data from the second article were included in this analysis. Of the eight studies, one was excluded, because survival was not assessed. 25 
Study characteristics
The patient characteristics and the protocol features for the seven trials included in this analysis are listed in Tables  1 and 2 . The trials ranged in size from 37 to 329 patients. There were a total of 977 patients. There were notable between-study differences with regard to types of disease and stages of disease that were eligible. In the French and EBMT trials, enrollment was restricted to patients with leukemia (ALL, AML, CML), while in a Canadian trial only patients with myeloid diseases (AML, CML, MDS) were eligible. 3, 5, 7 Patients with a wider variety of hematologic malignancies were enrolled in the other studies. The French and EBMT trials limited enrollment to patients with early-and intermediate-stage disease, and in both cases less than 15% of patients had intermediate-stage disease. 5, 7 In contrast, the other trials were open to patients with early, intermediate, and advanced-stage disease, and more than 25% of the patients in each of these studies had intermediate or advanced disease. Although we were able to verify that the proportion exceeded 25% for these five studies, we were not able to determine the precise proportion in each instance. However, in all five studies the proportion appeared to fall into the range of 26-50%.
The seven trials utilized varying doses of G-CSF for PBSC mobilization and differing targets for PBSC collections. As a result, for recipients of PBSC transplants, there were considerable between-study variations in the median number of transplanted CD34+ cells/kg (range 3.1-7.3 Â 10 6 ). For marrow recipients, the transplanted cell dose was also heterogeneous. In the trial conducted by Vigorito et al, 10 the median number of CD34+ cells/kg transplanted to marrow recipients was 5.3, and actually exceeded the median for blood recipients. For the other five studies, the median ranged from 1.5 to 2.7, and was less than the corresponding number for blood recipients. In three studies, all or nearly all of the patients were conditioned with Bu/Cy. A wide variety of regimens were used in the other four trials. All studies employed cyclosporine and short-course methotrexate as graftversus-host disease prophylaxis, but in two of the trials three rather than four doses of methotrexate were administered.
5,7 G-CSF was administered post transplant (to both marrow and blood recipients) in only one of the seven trials. 5 
Overall mortality
With a median reported duration of follow-up across studies of 24 months, 165 patients died out of 478 randomized to PBSCT, while 198 died out of 501 randomized to BMT. Studies ranged in size from 37 to 333 patients. The w 2 test for heterogeneity was 4.72 (6 df, P ¼ 0.58) and a formal estimation of the summary measure of effect was undertaken. The estimated odds ratio for mortality for PBSCT compared to BMT across these studies ranged from 0.50 to 1.18. (Table 3 and Figure 1 ). The summary odds ratio estimate for all studies was 0.81 (95% CI, 0.62, 1.05, z ¼ 1.60, P ¼ 0.11). The summary odds ratio for mortality for the two studies that reported a median blood CD34+ cell/kg dose less than 4 Â 10 6 was 0.59 (95% CI, 0.25, 1.40, P ¼ 0.2). 9, 11 For the five studies reporting median values of greater than or equal to 4 Â 10 6 , the summary odds ratio was 0.83 (95% CI, 0.63, 1.10, P ¼ 0.19).
3,5-7,10 The summary odds ratio for mortality for the five studies 3,6,9-11 (537 patients), where more than 25% of the enrolled subjects had intermediate-or advancedstage disease, was 0.64 (95% CI, 0.45, 0.91, P ¼ 0.01). For the two studies 5, 7 (440 patients) consisting predominantly of patients with early-stage disease, the summary estimate was 1.07 (95% CI, 0.73, 1.58, P ¼ 0.70).
Publication bias
Visual inspection of a funnel plot (not shown) did not reveal clear evidence of a publication bias, but the small number of studies limited the plot's utility. 
Discussion
We performed a meta-analysis of seven published RCTs in order to compare overall survival after HLA-matched sibling BMT and PBSCT for adults with hematologic malignancies. With a median duration of follow-up across all studies of 24 months, the summary odds ratio for mortality with PBSCT compared to BMT was not statistically significant (OR ¼ 0.81, 95% CI, 0.62, 1.05, P ¼ 0.11). The mortality estimates derived from each of the seven randomized controlled trials contained in this analysis ranged from 0.50 to 1.18. Through an exploration of heterogeneity, we sought to determine whether this variation was related to between-study differences in the proportion of patients enrolled with advanced-stage disease and in the median PBSCT CD34+ cell dose. Several studies have suggested that the survival benefit of PBSCT is limited to patients with more advanced-stage disease. In an analysis of EBMT and IBMTR registry data, which included 288 PBSCTs and 536 BMTs, 1-year leukemia-free survival rates were higher with PBSCT for patients with acute leukemia in second remission and chronic myelogenous leukemia in accelerated phase, but not for patients with less advanced disease (acute leukemia in first complete remission and chronic myelogenous leukemia in chronic phase). 2 In another registry study conducted by the EBMT of patients with myelodysplastic Table 2 Trial design, treatment protocols and graft characteristics Figure 1 Forest plot for all trials. The odds ratio for mortality (peripheral blood compared to bone marrow) and the corresponding 95% confidence interval are shown for each study.
syndrome, PBSCT was associated with improved survival for patients with RAEB, RAEB-T or IPSS Intermediate-2, or high-group disease, but not patients with less advanced disease. 12 Similarly, in two large randomized controlled trials included in our study, subgroup analyses demonstrated a survival advantage with PBSCT only for patients with more advanced disease. 3, 6 Consistent with these findings, our meta-analysis suggests that the differences in the proportion of patients with advanced disease between studies partly account for the discrepancies in survival outcomes. For studies where patients with more advanced disease comprised less than 25% of total enrollment the summary odds ratio was 1.07, while the summary estimate for the studies with more than 25% was 0.64.
The results of the aforementioned leukemia and myelodysplastic syndrome registry studies as well as the results of a Canadian multicenter trial suggest that any benefit from PBSC relative to BM for patients with advanced disease is attributable not to a decrease in the relapse rate, but rather to reduced transplant-related mortality. 2, 3, 12 These more heavily pretreated and therefore, likely more immunocompromised patients may benefit from the relatively rapid reconstitution of both innate and adoptive immunity, which occurs after PBSCT. 27 PBSCT has been shown not only to hasten neutrophil recovery, but also appears to lead to more prompt recovery of T and B cells. 4, 9 This improved lymphocyte recovery has been associated, in turn, with a reduced incidence of fatal infections in the late post transplant period (beyond post transplant day 30) infections. 4 A recent meta-analysis, comparing PBSC and BM transplantation, demonstrated a higher incidence of another cause of transplant-related mortality, chronic GVHD, with PBSC. 8 Additionally, updated findings from two of the clinical trials included in our analysis demonstrate that chronic GVHD that occurs post PBSCT is less responsive to treatment than that occurring post BMT. 28, 29 Since death from CGVHD may not occur for years post transplant, it is possible then that the apparent survival benefit of PBSCT for patients with advanced disease will diminish with longer follow-up.
Firm conclusions regarding the impact of disease stage on relative survival following PBSCT should not be drawn based on the results of our subgroup analysis. The studies differed in other ways that may have influenced survival, and the number of studies was too small to perform multivariate analysis, which would have allowed us to control for the effect of potential confounding variables.
Our analysis suggests that differences in PBSCT CD34+ cell dose were unrelated to discrepancies between studies regarding the relative effect of PBSCT on survival. The pooled relative risks for trials with median PBSCT doses of greater than four million were nearly identical to the pooled risk for trials with median doses of less than four million. While cell dose is an important determinant of survival after BMT and cord blood transplantation, this may not be true for PBSCT. [13] [14] [15] [16] [17] [18] In fact, in a European Blood and Transplant Group trial that was included in our analysis, higher CD34+ cell doses were associated with improved survival after BMT, but there was no relation between survival and cell dose after PBSCT. It may be that cell dose has an important impact on survival within the range typical of BMT, but not within the higher range, which is readily attainable with PBSCT. This supposition is supported by the findings of a British RCT, which was also included in our study. These investigators demonstrated increased mortality after BMT and PBSCT with transplanted cell doses of less than two million CD34+ cells/kg, but there appeared to be no benefit to higher cell doses. 30 Since the median PBSCT dose was well above this threshold for all seven trials included in our study, it is not surprising that we observed no association between cell dose and relative risk of mortality.
We cannot definitively exclude a publication bias. The graphical method we used to make this assessment a funnel plot is not easily applied to meta-analyses, such as ours, that include a small number of studies. Although nongraphical methods have been developed, these approaches are not widely accepted. 19 However, given the importance of this subject, and the relative lack of randomized controlled studies in our field, it seems unlikely that even small negative studies would go unpublished.
In summary, our meta-analysis of randomized controlled trials, comparing allogeneic PBSCT and BMT, indicates that variation in reported overall mortality partly stems from between-study differences in the proportion of patients enrolled with advanced-stage disease.
